Company intelligence / Profile preview
Shenzhen Boruijian Pharmaceutical
Shenzhen, Guangdong Sheng, Chinabraegen.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has at least two programs in Phase 1 clinical trials targeting neurodegenerative diseases such as Alzheimer’s and Lewy body disease. Its pipeline includes small molecules and radiopharmaceutical agents focused on nervous system disorders.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugRadiopharmaceuticals and diagnostic agentDiagnostic radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Shenzhen Boruijian Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Boruijian Pharmaceutical.